1

2
Teruo Oku, Kozo Sawada, Akio Kuroda, Kazuhiko Ohne, Atsushi Nomoto, Naomi Hosogai, Yoshimitsu Nakajima, Akira Nagashima, Keizo Sogabe, Kouichi Tamura, Masakazu Kobayashi: Indole derivatives as cGMP-PDE inhibitors. Fujisawa Pharmaceutical, Oblon Spivak McClelland Maier & Neustadt P C, May 30, 2000: US06069156 (51 worldwide citation)

Compounds of the formula (I): ##STR1## and their pharmaceutically acceptable compositions are useful in inhibiting the activity of cyclic guanosine 3',5'-monophosphate phosphodiesterase.


3
Teruo Oku, Chiyoshi Kasahara, Takehiko Ohkawa, Masashi Hashimoto: Oxaspiro�2,5! octane derivative. Fujisawa Pharmaceutical, Oblon Spivak McClelland Maier & Neustadt P C, June 16, 1998: US05767293 (39 worldwide citation)

Oxaspiro�2,5! octanes of the formula ##STR1## inhibit angiogenesis and are particularly suitable for the treatment of solid tumors. In preferred embodiments, R.sup.1 is a carbamoyl derivative, R.sup.2 is an alkoxy substituent and R.sup.3 is ##STR2## Pharmaceutical salts of these compounds, such as m ...


4

5
Yoshio Kawai, Hitoshi Yamazaki, Natsuko Kayakiri, Kousei Yoshihara, Takumi Yatabe, Teruo Oku: Benzofuran derivatives useful as inhibitors of bone resorption. Fujisawa Pharmaceutical, Oblon Spivak McClelland Maier & Neustadt P C, January 12, 1999: US05858995 (38 worldwide citation)

This invention relates to a novel heterocyclic compound represented by formula (I), wherein each symbol is as defined in the specification and a pharmaceutically acceptable salt thereof which are the inhibitors of bone resorption and bone metabolism, to processes for preparation thereof, to a pharma ...


6

7
Teruo Oku, Hiroshi Kayakiri, Shigeki Satoh, Yoshito Abe, Yuki Sawada, Takayuki Inoue, Hirokazu Tanaka: Bradykinin antagonist quinolines. Fujisawa Pharmaceutical, Oblon Spivak McClelland Maier & Neustadt P C, October 8, 1996: US05563162 (33 worldwide citation)

This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical ...


8

9

10